Grandfield & Dodd’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.1M | Sell |
36,415
-153
| -0.4% | -$117K | 1.59% | 18 |
|
|
2025
Q4 | $28.2M | Buy |
36,568
+117
| +0.3% | +$79.5K | 1.6% | 20 |
|
|
2025
Q3 | $20.5M | Buy |
36,451
+1,246
| +4% | +$705K | 1.16% | 32 |
|
|
2025
Q2 | $18.5M | Buy |
35,205
+1,998
| +6% | +$1.12M | 1.08% | 33 |
|
|
2025
Q1 | $21.1M | Buy |
33,207
+611
| +2% | +$420K | 1.31% | 27 |
|
|
2024
Q4 | $23.2M | Buy |
32,596
+268
| +0.8% | +$225K | 1.43% | 28 |
|
|
2024
Q3 | $34M | Sell |
32,328
-8
| -0% | -$8.9K | 2.01% | 16 |
|
|
2024
Q2 | $34M | Buy |
32,336
+59
| +0.2% | +$57.2K | 2.15% | 17 |
|
|
2024
Q1 | $31.1M | Buy |
32,277
+75
| +0.2% | +$71.3K | 1.96% | 19 |
|
|
2023
Q4 | $28.3M | Sell |
32,202
-40
| -0.1% | -$32.9K | 1.95% | 18 |
|
|
2023
Q3 | $26.5M | Buy |
32,242
+763
| +2% | +$600K | 1.95% | 19 |
|
|
2023
Q2 | $22.6M | Buy |
31,479
+554
| +2% | +$427K | 1.58% | 23 |
|
|
2023
Q1 | $25.4M | Buy |
30,925
+449
| +1% | +$339K | 1.78% | 22 |
|
|
2022
Q4 | $22M | Buy |
30,476
+204
| +0.7% | +$151K | 1.61% | 24 |
|
|
2022
Q3 | $20.9M | Buy |
30,272
+998
| +3% | +$628K | 1.7% | 22 |
|
|
2022
Q2 | $17.3M | Buy |
29,274
+500
| +2% | +$325K | 1.36% | 31 |
|
|
2022
Q1 | $20.1M | Buy |
28,774
+977
| +4% | +$618K | 1.36% | 31 |
|
|
2021
Q4 | $17.6M | Buy |
27,797
+1,766
| +7% | +$1.09M | 1.13% | 37 |
|
|
2021
Q3 | $15.8M | Buy |
26,031
+4,395
| +20% | +$2.73M | 1.1% | 40 |
|
|
2021
Q2 | $12.1M | Buy |
21,636
+3,074
| +17% | +$1.56M | 0.84% | 45 |
|
|
2021
Q1 | $8.78M | Buy |
18,562
+807
| +5% | +$393K | 0.66% | 47 |
|
|
2020
Q4 | $8.58M | Buy |
17,755
+1,085
| +7% | +$586K | 0.67% | 47 |
|
|
2020
Q3 | $9.33M | Buy |
16,670
+9
| +0.1% | +$5.46K | 0.84% | 44 |
|
|
2020
Q2 | $10.4M | Sell |
16,661
-423
| -2% | -$240K | 1.01% | 41 |
|
|
2020
Q1 | $8.34M | Buy |
17,084
+1,119
| +7% | +$462K | 0.98% | 38 |
|
|
2019
Q4 | $6M | Buy |
15,965
+2,348
| +17% | +$790K | 0.55% | 52 |
|
|
2019
Q3 | $3.78M | Buy |
13,617
+2,019
| +17% | +$597K | 0.37% | 60 |
|
|
2019
Q2 | $3.63M | Buy |
11,598
+2,620
| +29% | +$872K | 0.36% | 61 |
|
|
2019
Q1 | $3.69M | Buy |
8,978
+283
| +3% | +$117K | 0.38% | 60 |
|
|
2018
Q4 | $3.25M | Buy |
8,695
+1,522
| +21% | +$557K | 0.38% | 61 |
|
|
2018
Q3 | $2.9M | Buy |
7,173
+1,327
| +23% | +$505K | 0.3% | 70 |
|
|
2018
Q2 | $2.02M | Buy |
5,846
+3,401
| +139% | +$1.06M | 0.22% | 75 |
|
|
2018
Q1 | $842K | Buy |
2,445
+711
| +41% | +$247K | 0.09% | 102 |
|
|
2017
Q4 | $652K | Buy |
1,734
+87
| +5% | +$35.2K | 0.07% | 115 |
|
|
2017
Q3 | $736K | Buy |
1,647
+115
| +8% | +$54.7K | 0.08% | 104 |
|
|
2017
Q2 | $752K | Buy |
1,532
+35
| +2% | +$15.3K | 0.09% | 106 |
|
|
2017
Q1 | $580K | Buy |
1,497
+17
| +1% | +$6.3K | 0.07% | 116 |
|
|
2016
Q4 | $543K | Buy |
1,480
+180
| +14% | +$68.4K | 0.07% | 118 |
|
|
2016
Q3 | $523K | Buy |
1,300
+125
| +11% | +$50.1K | 0.07% | 115 |
|
|
2016
Q2 | $410K | Buy |
1,175
+48
| +4% | +$18.5K | 0.06% | 124 |
|
|
2016
Q1 | $406K | Buy |
1,127
+347
| +44% | +$143K | 0.06% | 119 |
|
|
2015
Q4 | $423K | Buy |
780
+107
| +16% | +$58K | 0.06% | 116 |
|
|
2015
Q3 | $313K | Sell |
673
-26
| -4% | -$14K | 0.05% | 134 |
|
|
2015
Q2 | $357K | Sell |
699
-43
| -6% | -$21K | 0.05% | 132 |
|
|
2015
Q1 | $335K | Hold |
742
| – | – | 0.05% | 130 |
|
|
2014
Q4 | $304K | Hold |
742
| – | – | 0.05% | 140 |
|
|
2014
Q3 | $268K | Buy |
742
+20
| +3% | +$6.7K | 0.04% | 141 |
|
|
2014
Q2 | $204K | Buy |
722
+45
| +7% | +$13.3K | 0.03% | 172 |
|
|
2014
Q1 | $203K | Buy |
+677
| New | +$209K | 0.03% | 169 |
|
Other funds holding REGN
VCM
N
Grandfield & Dodd's REGN Position: Q1 2026 in Review
Grandfield & Dodd reduced its Regeneron Pharmaceuticals (REGN) stake by 0.42% in Q1 2026, selling an estimated $117K and leaving 36,415 shares worth $28.1M. The position accounts for 1.59% of the portfolio, ranked #18.
Grandfield & Dodd first reported a position in REGN in Q1 2014 and has held it in 49 quarters since. The position peaked at $34M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Grandfield & Dodd held 36,415 shares of Regeneron Pharmaceuticals worth $28.1M as of Q1 2026.
- Grandfield & Dodd sold 153 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $117K.
- Regeneron Pharmaceuticals made up 1.59% of Grandfield & Dodd's portfolio in Q1 2026, its #18 holding.
- Grandfield & Dodd first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
- Grandfield & Dodd's Regeneron Pharmaceuticals position peaked at $34M in Q2 2024.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.